Zicam and Vicks Win Over Cold Medicine Shoppers, But Loyalty Lies With Price and Symptom Relief: Report
- Consumer Goods & Services
Fallon Wolken
- 0
- 3 minutes read
Only 11% of searches were for specific brands.
The cold medicine market has proved to be a difficult landscape to gain market share in as consumers prioritize symptom relief over brand loyalty.
Using U.S. Amazon data, a recent study by CommerceIQ found that the market grew in product sales by an average of 18% in the fourth quarter of 2024 from Q3. While brands such as Zicam and Vicks are seeing notable growth, consumers are increasingly focused on medicine products that do the trick but don’t break the bank.
Only 11% of searches were for specific brands and mid-range SKUs ($6–$15) accounted for over 70% of unit sales across all product categories.
Also read: RxSugar Seizes GLP-1 Opportunities With PIM Investments
